| Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis AR Ferreira, A Di Meglio, B Pistilli, AS Gbenou, M El-Mouhebb, S Dauchy, ... Annals of Oncology 30 (11), 1784-1795, 2019 | 157 | 2019 |
| Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients M Lambertini, O Goldrat, AR Ferreira, J Dechene, HA Azim Jr, J Desir, ... Annals of oncology 29 (1), 237-243, 2018 | 109 | 2018 |
| Bone metastasis risk factors in breast cancer C Pulido, I Vendrell, AR Ferreira, S Casimiro, A Mansinho, I Alho, L Costa Ecancermedicalscience 11, 2017 | 106 | 2017 |
| Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk B Pistilli, A Paci, AR Ferreira, A Di Meglio, V Poinsignon, A Bardet, ... Journal of Clinical Oncology 38 (24), 2762, 2020 | 93 | 2020 |
| Bone remodeling markers and bone metastases: From cancer research to clinical implications A Ferreira, I Alho, S Casimiro, L Costa BoneKEy reports 4, 2015 | 60 | 2015 |
| ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe I Vaz-Luis, M Masiero, G Cavaletti, A Cervantes, RT Chlebowski, ... Annals of oncology 33 (11), 1119-1133, 2022 | 58 | 2022 |
| Molecular mechanisms of bone metastasis: which targets came from the bench to the bedside? S Casimiro, AR Ferreira, A Mansinho, I Alho, L Costa International journal of molecular sciences 17 (9), 1415, 2016 | 53 | 2016 |
| Mixed invasive ductal and lobular carcinoma of the breast: prognosis and the importance of histologic grade O Metzger‐Filho, AR Ferreira, R Jeselsohn, WT Barry, DA Dillon, JE Brock, ... The oncologist 24 (7), e441-e449, 2019 | 44 | 2019 |
| Breast cancer surgery with augmented reality PF Gouveia, J Costa, P Morgado, R Kates, D Pinto, C Mavioso, J Anacleto, ... The Breast 56, 14-17, 2021 | 42 | 2021 |
| Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial M Lambertini, C Campbell, RD Gelber, G Viale, A McCullough, F Hilbers, ... Breast cancer research and treatment 177, 103-114, 2019 | 39 | 2019 |
| Patterns of care and clinical outcomes of HER2-positive metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab … M Lambertini, AR Ferreira, A Di Meglio, F Poggio, F Puglisi, F Sottotetti, ... Clinical breast cancer 17 (8), 601-610. e2, 2017 | 36 | 2017 |
| Weekly docetaxel and low-dose estramustine phosphate in hormone refractory prostate cancer: a phase II study MP Kosty, A Ferreira, T Bryntesen, J Grossman Proc Am Soc Clin Oncol 20 (152b), 2360, 2001 | 36 | 2001 |
| Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer S Martel, E Poletto, AR Ferreira, M Lambertini, F Sottotetti, I Bertolini, ... The Breast 37, 142-147, 2018 | 35 | 2018 |
| Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases AR Ferreira, M Bettencourt, I Alho, AL Costa, AR Sousa, A Mansinho, ... Journal of Bone Oncology 6, 16-21, 2017 | 31 | 2017 |
| Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (neo) adjuvant trastuzumab: an … M Lambertini, AR Ferreira, F Poggio, F Puglisi, A Bernardo, F Montemurro, ... The Oncologist 20 (8), 880-889, 2015 | 29 | 2015 |
| Dynamic modeling of bone metastasis, microenvironment and therapy: Integrating parathyroid hormone (PTH) effect, anti-resorptive and anti-cancer therapy RM Coelho, JM Lemos, I Alho, D Valério, AR Ferreira, L Costa, S Vinga Journal of Theoretical Biology 391, 1-12, 2016 | 26 | 2016 |
| Levels of circulating fibroblast growth factor 23 (FGF23) and prognosis in cancer patients with bone metastases A Mansinho, AR Ferreira, S Casimiro, I Alho, I Vendrell, AL Costa, ... International Journal of Molecular Sciences 20 (3), 695, 2019 | 23 | 2019 |
| Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: a systematic review and … S Martel, M Bruzzone, M Ceppi, C Maurer, NF Ponde, AR Ferreira, ... Cancer treatment reviews 62, 123-132, 2018 | 23 | 2018 |
| Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis M Brandão, C Maurer, PK Ziegelmann, NF Pondé, A Ferreira, S Martel, ... ESMO open 5 (4), e000842, 2020 | 20 | 2020 |
| N-telopeptide of type I collagen long-term dynamics in breast cancer patients with bone metastases: clinical outcomes and influence of extraskeletal metastases AR Ferreira, I Alho, N Shan, M Matias, M Faria, S Casimiro, K Leitzel, S Ali, ... The Oncologist 21 (12), 1418-1426, 2016 | 20 | 2016 |
Inês LuísInstructorVerified email at dfci.harvard.edu
